Technology Transfer Officer Sample Clauses

Technology Transfer Officer. Surname Weetall Forenames Xxxxx L Title (Dr etc.) Director Pharmacology, (Ph.D.) Q2 Title of project: (no more than 220 characters) Discovery and development of a novel glioblastoma treatment that selectively reduces Bmi-1 expression in tumour stem cells Q3 Company name and address or department name and address at administering institution: PTC Therapeutics, Inc. 000 Xxxxxxxxx Xx Xxxxx Xxxxxxxxxx, XX 00000 XXX Q4 Type of Translation Award requested: SEEDING DRUG DISCOVERY Q5 Period for which support is sought: (state in months) 30 Q6 Proposed start date: (dd/mm/yy) 01/07/2010 Principal Applicant Name Xxxxxx X. Xxxxx, Ph.D. Telephone numbers: Contact address PTC Therapeutics, Inc. Day [**] 000 Xxxxxxxxx Xxxxx Mobile [**] Xxxxx Xxxxxxxxxx, XX 00000 Fax. [**] e-mail [**]
Sample 1Sample 2
AutoNDA by SimpleDocs
Technology Transfer Officer. Surname Forenames Title (Dr etc.) Q2 Title of project: (no more than 220 characters) A First-in-Human Phase I Clinical Trial for the Novel Clostridium difficile Antibiotic SMT19969 Q3 Company name and address or department name and address at administering institution: Summit PLC, 91 Xxxxxx Xxxx, Abingdon, Oxfordshire, OX14 4RY Q4 Type of Translation Award requested: (Strategic Awards by prior agreement only) TRANSLATION AWARD Q5 Period for which support is sought: (state in months) 12 Q6 Proposed start date: (dd/mm/yy) 06/08/2012 FRONT PAGE 71 TA 02/12 Principal Applicant Name Rixxxxx Xxxxxxx Telephone numbers: Contact address 91 Xxxxxx Xxxx Xxxxxxxx Oxfordshire OX14 4RY Day [**] Mobile [**] Fax. [**]
Sample 1Sample 2
Technology Transfer Officer. Surname Xxxxxxx Forenames Don Title (Dr etc.) Mr Q2 Title of project: (no more than 220 characters) Lead Optimisation and development of novel bacterial DNA synthesis inhibitors for the treatment of nosocomial infections caused by multi-drug resistant Gram-negative bacteria Q3 Company name and address or department name and address at administering institution: PTC Therapeutics, Inc., 000 Xxxxxxxxx Xxxxx, Xxxxx Xxxxxxxxxx, XX 00000 Q4 Type of Translation Award requested: SEEDING DRUG DISCOVERY Q5 Period for which support is sought:(state in months) 30 months Q6 Proposed start date: (dd/mm/yy) 01/01/12 Principal Applicant Name Xxxx Xxxxxx V.N. Xxxxxxx Telephone numbers: Contact address PTC Therapeutics, Inc Day [**] 000 Xxxxxxxxx Xxxxx Xxxxx Xxxxxxxxxx, XX 00000 Mobile [**] USA Fax. [**] e-mail [**] Coapplicant (1) Name Xxxxxx Xxxxxxxxx Telephone numbers: Contact address PTC Therapeutics, Inc Day [**] 000 Xxxxxxxxx Xxxxx Xxxxx Xxxxxxxxxx, XX 00000 Mobile [**] USA Fax, [**] e-mail [**] Coapplicant (2) Name Telephone numbers: Contact address Day Mobile Fax. e-mail Technology Transfer Officer Name Xxx Xxxxxxx Telephone numbers: Contact address PTC Therapeutics, Inc Day [**] 000 Xxxxxxxxx Xxxxx Xxxxx Xxxxxxxxxx, XX 00000 Mobile USA Fax. [**] e-mail [**] Drug Discovery Advisor Name Xxxxxx X. Xxxxxxxx Telephone numbers: Contact address PTC Therapeutics, Inc Day [**] 000 Xxxxxxxxx xxxxx Xxxxx Xxxxxxxxxx, XX 00000 Mobile [**] USA Fax. [**] e-mail [**] Contact details If a company please provide the following: Company number: 1-908-222-7000 Date and place of incorporation: March 31, 1998, Delaware Shared capital: Authorised: Preferred Stock – 156,995,095, Common Stock – 26,000,000 Issued: Preferred – 154,728,267, Common – 130,586 Details of Project Registered holders (name, number and type): Credit Suisse First Boston Equity Partners,
Sample 1
Technology Transfer Officer. Surname Xxxxxxx Forenames Don Title (Dr etc.) Mr Q2 Title of project: (no more than 220 characters) Lead Optimisation and development of novel bacterial DNA synthesis inhibitors for the treatment of nosocomial infections caused by multi-drug resistant Gram-negative bacteria Q3 Company name and address or department name and address at administering institution: PTC Therapeutics, Inc., 000 Xxxxxxxxx Xxxxx, Xxxxx Xxxxxxxxxx, XX 00000 Q4 Type of Translation Award requested: SEEDING DRUG DISCOVERY Q5 Period for which support is sought:(state in months) 30 months Q6 Proposed start date: (dd/mm/yy) 01/01/12 Principal Applicant Name Xxxx Xxxxxx V.N. Xxxxxxx Telephone numbers: Contact address PTC Therapeutics, Inc Day [**] 000 Xxxxxxxxx Xxxxx Xxxxx Xxxxxxxxxx, XX 00000 Mobile [**] USA Fax. [**] e-mail [**]
Sample 1

Related to Technology Transfer Officer

  • Technology Transfer Subject to the terms of the Development Supply Agreement, as soon as reasonably practicable, but in no event later than the fifth (5th) anniversary of the Effective Date, Alnylam shall initiate a technology transfer to MedCo, or to its Third Party manufacturer(s) of Licensed Product, selected by MedCo and reasonably acceptable to Alnylam, of Alnylam Know-How that is reasonably necessary or useful for the Manufacture of the Licensed Product, and shall make available its personnel on a reasonable basis to consult with MedCo or such Third Party manufacturer(s) with respect thereto, all at MedCo’s expense, including the Costs reasonably incurred by Alnylam in connection with such technology transfer activities. MedCo shall reimburse Alnylam such Costs incurred with respect to such Manufacturing technology transfer within [***] days after receipt of an invoice therefor. Alnylam and its Affiliates shall keep complete and accurate records in sufficient detail to enable the payments payable hereunder to be determined. Alnylam shall not be required to perform technology transfer to more than one Third Party manufacturer for each stage of the Licensed Product supply chain (i.e., Bulk Drug Substance, Bulk Drug Product and Finished Product). Promptly after MedCo’s written request, Alnylam shall use Commercially Reasonable Efforts to assign to MedCo any manufacturing agreement between Alnylam and a Third Party that is solely related to the manufacture of Licensed Products. Such assignment shall be subject to the terms and conditions of such agreement, including any required consents of such Third Party and MedCo’s written agreement to assume all the obligations of Alnylam under such agreement to be undertaken after such assignment, but Alnylam shall remain solely responsible for its obligations under such agreement arising prior to such assignment. Except as provided in the immediately preceding sentence, MedCo shall be solely responsible for contracting with such Third Party manufacturer (and any other Third Party manufacture to whom Alnylam has initiated technology transfer as set forth in this Section 5.3) for the supply of such Licensed Product and Alnylam shall have no obligations under such agreement between MedCo and such Third Party manufacturer. Alnylam shall use Commercially Reasonable Efforts to obtain any such consent in a form reasonably acceptable to MedCo.

  • Business Development Company Status The Company, during a period of at least 12 months from the Closing Time, will use its commercially reasonable efforts to maintain its status as a business development company; provided, however, the Company may cease to be, or withdraw its election as, a business development company, with the approval of the board of directors and a vote of stockholders as required by Section 58 of the 1940 Act or any successor provision.

  • Resignation as Officer or Director Upon a termination of employment, unless requested otherwise by the Company, the Executive shall resign each position (if any) that the Executive then holds as a director or officer of the Company or of any affiliates of the Company. The Executive’s execution of this Agreement shall be deemed the grant by the Executive to the officers of the Company of a limited power of attorney to sign in the Executive’s name and on the Executive’s behalf any such documentation as may be required to be executed solely for the limited purposes of effectuating such resignations.

Time is Money Join Law Insider Premium to draft better contracts faster.